A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand.
The DOI matches its Crossref record.
Abstract
The efficacy-safety and pharmacokinetics of the six-dose regimen of artemether-lumefantrine (Coartem/Riamet; Novartis Pharma AG, Basel, Switzerland) were assessed in a randomized trial in 219 patients (> or = 12 years old) with acute, uncomplicated Plasmodium falciparum malaria in Thailand. One hundred and sixty-four patients received artemether-lumefantrine and 55 received the standard treatment combination of mefloquine-artesunate. Both drugs induced rapid clearance of parasites and malaria symptoms. The 28-day cure rates were 95.5% (90% confidence interval [CI] = 91.7, 97.9%) for artemether-lumefantrine and 100% (90% CI = 94.5, 100%) for mefloquine-artesunate. This high-dose regimen of artemether-lumefantrine was very well tolerated, with very good compliance. The most frequent adverse events were headache, dizziness, nausea, abdominal pain, dyspepsia, vomiting, and skin rash. Overall, only 2% of patients in both groups showed QTc prolongations but without any cardiac complication, and no differences were seen between patients with and without measurable baseline plasma levels of quinine or mefloquine. Plasma levels of artemether, dihydroartemisinin, and lumefantrine were consistent with historical data for the same dose regimen, and were higher, particularly for lumefantrine, than those previously observed with the four-dose regimen, explaining the greater efficacy of the six-dose regimen in a drug-resistant setting. These results confirm the excellent safety and efficacy of the six-dose regimen of artemether-lumefantrine in the treatment of multidrug-resistant P. falciparum malaria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Research conducted in Ethiopia, Mali, Zambia, Thailand and Uganda has shown the maximum parasitaemia clearance time was at the seventh day of study period [11, 15, 20, 23, 24].”
In the citing paper
“which is in line with WHO recommendation and researches conducted in Ethiopia, Thailand and elsewhere [11, 14, 15, 20].”
In the citing paper
“However, studies conducted in Zanzibar, Thailand and Japan show treatment failure and the evolving of drug-resistant parasite gene pfmdr1 86 N for the drug [11, 16, 17].”
In the citing paper
“After the implementation of AL as the drug of choice, a radical reduction in malaria cases occurred in most African countries: Rwanda (64 %), Zambia (29 %) and Ghana (13 %) between 2000 and 2007 [11, 12].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bousema, T., & Drakeley, C. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-10 · Cited by 746
Wiesner, J., Ortmann, R., Jomaa, H., & Schlitzer, M. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200569 · Cited by 428
WHO Guidelines for the treatment of malaria
Kunte, R., & Kunwar, R. (2011) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(16)30022-3 · Cited by 341
Price, R. N., Uhlemann, A.-C., van Vugt, M., Brockman, A., Hutagalung, R., Nair, S., Nash, D., Singhasivanon, P., Anderson, T. J. C., Krishna, S., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/503423 · Cited by 317
Artemisinin-based combination therapy for treating uncomplicated malaria
Sinclair, D., Zani, B., Donegan, S., Olliaro, P., & Garner, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007483.pub2 · Cited by 286
Assefa, A., Kassa, M., Tadese, G., Mohamed, H., Animut, A., & Mengesha, T. (2010) · Parasites & Vectors · doi:10.1186/1756-3305-3-1 · Cited by 267
Piola, P., Fogg, C., Bajunirwe, F., Biraro, S., Grandesso, F., Ruzagira, E., Babigumira, J., Kigozi, I., Kiguli, J., Kyomuhendo, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66416-1 · Cited by 211
McGready, R., Stepniewska, K., Lindegardh, N., Ashley, E. A., La, Y., Singhasivanon, P., White, N. J., & Nosten, F. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0199-7 · Cited by 115
Manyando, C., Kayentao, K., D’Alessandro, U., Okafor, H. U., Juma, E., & Hamed, K. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-141 · Cited by 62
“Small changes in AL exposure during pregnancy have been reported [21,25], but these results should be viewed with caution as they involve inter-trial comparisons, small populations, high inter-individual variation in plasma levels and the average plasma levels reported are comparable with data from non-pregnant adults…”
MethodResultTarning, J., Kloprogge, F., Piola, P., Dhorda, M., Muwanga, S., Turyakira, E., Nuengchamnong, N., Nosten, F., Day, N. P., White, N. J., et al. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-293 · Cited by 43
Bruxvoort, K., Festo, C., Cairns, M., Kalolella, A., Mayaya, F., Kachur, S. P., Schellenberg, D., & Goodman, C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134275 · Cited by 37
Abdulla, S., Amuri, B., Kabanywanyi, A. M., Ubben, D., Reynolds, C., Pascoe, S., Fitoussi, S., Yeh, C.-M., Nuortti, M., Séchaud, R., et al. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-253 · Cited by 34
“The dispersible tablet and the tablet administered crushed were both highly effective and appeared well tolerated and safe, consistent with historical data gathered with the intact tablet [9,27-29].”
BackgroundEbstie, Y. A., Zeynudin, A., Belachew, T., Desalegn, Z., & Suleman, S. (2015) · Malaria Journal · doi:10.1186/s12936-015-0744-x · Cited by 24
Mobile Phone Short Message Service to Improve Malaria Pharmacoadherence in Zambia
Steury, E. E. (2016) · Journal of Nursing Scholarship · doi:10.1111/jnu.12216 · Cited by 8
Metadata
- Authors
- Lefèvre, G., Looareesuwan, S., Treeprasertsuk, S., Krudsood, S., Silachamroon, U., Gathmann, I., Mull, R., & Bakshi, R.
- Venue
- The American journal of tropical medicine and hygiene
- Published
- 2001-05
- Volume
- 64
- Issue
- 5
- Pages
- 247-256
- ISSN
- 0002-9637 (ISSN-L)
- OpenAlex
- W2134089025
- Cited by
- 178
- References
- 0
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.